Disease · MONDO_0015447
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lenvatinib 24 mg vs Lenvatinib 18 mg: deaths from any cause | 11 of 75 | 19 of 77 | 152 | NCT02702388 | Trial comparisons |
| Lenvatinib 24 mg vs Lenvatinib 18 mg: serious adverse events | 26 of 75 | 35 of 77 | 152 | NCT02702388 | Trial comparisons |
| 99Tc-MDP vs Fosamax: deaths from any cause | 0 of 70 | 0 of 72 | 142 | NCT02304757 | Trial comparisons |
| 99Tc-MDP vs Fosamax: serious adverse events | 0 of 70 | 0 of 72 | 142 | NCT02304757 | Trial comparisons |
| DTC Cohort vs MTC Cohort: deaths from any cause | 44 of 58 | 37 of 59 | 117 | NCT00784303 | Trial comparisons |
| DTC Cohort vs MTC Cohort: serious adverse events | 32 of 58 | 42 of 59 | 117 | NCT00784303 | Trial comparisons |
Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) | 9 of 38 | 7 of 25 | 63 | NCT00381641 | Trial comparisons |
Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: Incidence of Toxicity, Graded According to the Common Terminology Criteria for Adverse Events Version 3.0 | 38 of 38 | 24 of 25 | 63 | NCT00381641 | Trial comparisons |
| Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: deaths from any cause | 21 of 38 | 5 of 25 | 63 | NCT00381641 | Trial comparisons |
| Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: serious adverse events | 17 of 38 | 12 of 25 | 63 | NCT00381641 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 7 of 30 | 19 of 25 | 55 | NCT02973997 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 16 of 30 | 8 of 25 | 55 | NCT02973997 | Trial comparisons |
| Cohort 1 vs Cohort 2: Number of Patients Experiencing Grade 3+ Adverse Events | 26 of 29 | 14 of 25 | 54 | NCT02973997 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015447/comparisons